{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T09:44:30Z","timestamp":1771667070547,"version":"3.50.1"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,13]]},"DOI":"10.7759\/cureus.43404","type":"journal-article","created":{"date-parts":[[2023,8,13]],"date-time":"2023-08-13T12:02:06Z","timestamp":1691928126000},"source":"Crossref","is-referenced-by-count":4,"title":["Irritable Bowel Syndrome: Treating the Gut and Brain\/Mind at the Same Time"],"prefix":"10.7759","author":[{"given":"Maleesha","family":"Jayasinghe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A","family":"Damianos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omesh","family":"Prathiraja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melysze D","family":"Oorloff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gairu M","family":"Nagalmulla K","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adithya","family":"Nadella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilushini","family":"Caldera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Mohtashim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2021.04.029","article-title":"Irritable bowel syndrome","volume":"158","author":"Sebasti\u00e1n Domingo JJ","year":"2022","unstructured":"Sebasti\u00e1n Domingo JJ. Irritable bowel syndrome. Med Clin (Barc). 2022, 158:76-81. 10.1016\/j.medcli.2021.04.029","journal-title":"Med Clin (Barc)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12051725","article-title":"Procedures in fecal microbiota transplantation for treating irritable bowel syndrome: systematic review and meta-analysis","volume":"12","author":"Rodrigues T","year":"2023","unstructured":"Rodrigues T, Rodrigues Fialho S, Ara\u00fajo JR, Rocha R, Moreira-Ros\u00e1rio A. Procedures in fecal microbiota transplantation for treating irritable bowel syndrome: systematic review and meta-analysis. J Clin Med. 2023, 12:1725. 10.3390\/jcm12051725","journal-title":"J Clin Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1607547","article-title":"Irritable bowel syndrome","volume":"376","author":"Ford AC","year":"2017","unstructured":"Ford AC, Lacy BE, Talley NJ. Irritable bowel syndrome. N Engl J Med. 2017, 376:2566-78. 10.1056\/NEJMra1607547","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7326\/AITC201706060","article-title":"Irritable bowel syndrome","volume":"166","author":"Sultan S","year":"2017","unstructured":"Sultan S, Malhotra A. Irritable bowel syndrome. Ann Intern Med. 2017, 166:ITC81-96. 10.7326\/AITC201706060","journal-title":"Ann Intern Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i22.6759","article-title":"Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine","volume":"20","author":"Saha L","year":"2014","unstructured":"Saha L. Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol. 2014, 20:6759-73. 10.3748\/wjg.v20.i22.6759","journal-title":"World J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.22532","article-title":"Diagnosis and treatment of irritable bowel syndrome: a review","volume":"325","author":"Camilleri M","year":"2021","unstructured":"Camilleri M. Diagnosis and treatment of irritable bowel syndrome: a review. JAMA. 2021, 325:865-77. 10.1001\/jama.2020.22532","journal-title":"JAMA"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S174982","article-title":"The role of inflammation in irritable bowel syndrome (IBS)","volume":"11","author":"Ng QX","year":"2018","unstructured":"Ng QX, Soh AY, Loke W, Lim DY, Yeo WS. The role of inflammation in irritable bowel syndrome (IBS). J Inflamm Res. 2018, 11:345-9. 10.2147\/JIR.S174982","journal-title":"J Inflamm Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.28064","article-title":"The role of gut-microbiota in the pathophysiology and therapy of irritable bowel syndrome: a systematic review","volume":"14","author":"Shrestha B","year":"2022","unstructured":"Shrestha B, Patel D, Shah H, et al.. The role of gut-microbiota in the pathophysiology and therapy of irritable bowel syndrome: a systematic review. Cureus. 2022, 14:e28064. 10.7759\/cureus.28064","journal-title":"Cureus"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.14339","article-title":"Mast cell mediation of visceral sensation and permeability in irritable bowel syndrome","volume":"34","author":"Hasler WL","year":"2022","unstructured":"Hasler WL, Grabauskas G, Singh P, Owyang C. Mast cell mediation of visceral sensation and permeability in irritable bowel syndrome. Neurogastroenterol Motil. 2022, 34:e14339. 10.1111\/nmo.14339","journal-title":"Neurogastroenterol Motil"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-014-0502-z","article-title":"Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis","volume":"264","author":"Fond G","year":"2014","unstructured":"Fond G, Loundou A, Hamdani N, et al.. Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2014, 264:651-60. 10.1007\/s00406-014-0502-z","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s10354-017-0592-0","article-title":"Intestinal microbiome-gut-brain axis and irritable bowel syndrome","volume":"168","author":"Moser G","year":"2018","unstructured":"Moser G, Fournier C, Peter J. Intestinal microbiome-gut-brain axis and irritable bowel syndrome. Wien Med Wochenschr. 2018, 168:62-6. 10.1007\/s10354-017-0592-0","journal-title":"Wien Med Wochenschr"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0705762","article-title":"Role of serotonin in the pathophysiology of the irritable bowel syndrome","volume":"141","author":"Crowell MD","year":"2004","unstructured":"Crowell MD. Role of serotonin in the pathophysiology of the irritable bowel syndrome. Br J Pharmacol. 2004, 141:1285-93. 10.1038\/sj.bjp.0705762","journal-title":"Br J Pharmacol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00664","article-title":"Small intestinal bacterial overgrowth and irritable bowel syndrome - an update","volume":"11","author":"Takakura W","year":"2020","unstructured":"Takakura W, Pimentel M. Small intestinal bacterial overgrowth and irritable bowel syndrome - an update. Front Psychiatry. 2020, 11:664. 10.3389\/fpsyt.2020.00664","journal-title":"Front Psychiatry"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2010.12.011","article-title":"The role of genetics in IBS","volume":"40","author":"Saito YA","year":"2011","unstructured":"Saito YA. The role of genetics in IBS. Gastroenterol Clin North Am. 2011, 40:45-67. 10.1016\/j.gtc.2010.12.011","journal-title":"Gastroenterol Clin North Am"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.pop.2017.07.009","article-title":"Irritable bowel syndrome: epidemiology, pathophysiology, diagnosis, and treatment","volume":"44","author":"Defrees DN","year":"2017","unstructured":"Defrees DN, Bailey J. Irritable bowel syndrome: epidemiology, pathophysiology, diagnosis, and treatment. Prim Care. 2017, 44:655-71. 10.1016\/j.pop.2017.07.009","journal-title":"Prim Care"},{"key":"ref16","article-title":"Irritable Bowel Syndrome","author":"Patel N","year":"2022","unstructured":"Patel N, Shackelford K. Irritable Bowel Syndrome. StatPearls Publishing, Treasure Island, FL; 2022."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-050218-013625","article-title":"Low-FODMAP diet for irritable bowel syndrome: what we know and what we have yet to learn","volume":"71","author":"Liu J","year":"2020","unstructured":"Liu J, Chey WD, Haller E, Eswaran S. Low-FODMAP diet for irritable bowel syndrome: what we know and what we have yet to learn. Annu Rev Med. 2020, 71:303-14. 10.1146\/annurev-med-050218-013625","journal-title":"Annu Rev Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/nu11081824","article-title":"Diet in irritable bowel syndrome (IBS): interaction with gut microbiota and gut hormones","volume":"11","author":"El-Salhy M","year":"2019","unstructured":"El-Salhy M, Hatlebakk JG, Hausken T. Diet in irritable bowel syndrome (IBS): interaction with gut microbiota and gut hormones. Nutrients. 2019, 11:1824. 10.3390\/nu11081824","journal-title":"Nutrients"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2017.1371793","article-title":"Enteroendocrine, Musashi 1 and neurogenin 3 cells in the large intestine of Thai and Norwegian patients with irritable bowel syndrome","volume":"52","author":"El-Salhy M","year":"2017","unstructured":"El-Salhy M, Patcharatrakul T, Hatlebakk JG, Hausken T, Gilja OH, Gonlachanvit S. Enteroendocrine, Musashi 1 and neurogenin 3 cells in the large intestine of Thai and Norwegian patients with irritable bowel syndrome. Scand J Gastroenterol. 2017, 52:1331-9. 10.1080\/00365521.2017.1371793","journal-title":"Scand J Gastroenterol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.01136","article-title":"The microbiome and irritable bowel syndrome - a review on the pathophysiology, current research and future therapy","volume":"10","author":"Chong PP","year":"2019","unstructured":"Chong PP, Chin VK, Looi CY, Wong WF, Madhavan P, Yong VC. The microbiome and irritable bowel syndrome - a review on the pathophysiology, current research and future therapy. Front Microbiol. 2019, 10:1136. 10.3389\/fmicb.2019.01136","journal-title":"Front Microbiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.14356","article-title":"Long-term personalized low FODMAP diet in IBS","volume":"34","author":"De Palma G","year":"2022","unstructured":"De Palma G, Bercik P. Long-term personalized low FODMAP diet in IBS. Neurogastroenterol Motil. 2022, 34:e14356. 10.1111\/nmo.14356","journal-title":"Neurogastroenterol Motil"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.02.058","article-title":"Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence","volume":"6","author":"Shepherd SJ","year":"2008","unstructured":"Shepherd SJ, Parker FC, Muir JG, Gibson PR. Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. Clin Gastroenterol Hepatol. 2008, 6:765-71. 10.1016\/j.cgh.2008.02.058","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-311339","article-title":"FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial","volume":"66","author":"McIntosh K","year":"2017","unstructured":"McIntosh K, Reed DE, Schneider T, et al.. FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial. Gut. 2017, 66:1241-51. 10.1136\/gutjnl-2015-311339","journal-title":"Gut"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-313750","article-title":"The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS","volume":"66","author":"Staudacher HM","year":"2017","unstructured":"Staudacher HM, Whelan K. The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS. Gut. 2017, 66:1517-27. 10.1136\/gutjnl-2017-313750","journal-title":"Gut"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13686","article-title":"How to institute the low-FODMAP diet","volume":"32","author":"Barrett JS","year":"2017","unstructured":"Barrett JS. How to institute the low-FODMAP diet. J Gastroenterol Hepatol. 2017, 32:8-10. 10.1111\/jgh.13686","journal-title":"J Gastroenterol Hepatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.09.046","article-title":"A diet low in FODMAPs reduces symptoms of irritable bowel syndrome","volume":"146","author":"Halmos EP","year":"2014","unstructured":"Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014, 146:67-75.e5. 10.1053\/j.gastro.2013.09.046","journal-title":"Gastroenterology"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/nqab005","article-title":"Low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet compared with traditional dietary advice for diarrhea-predominant irritable bowel syndrome: a parallel-group, randomized controlled trial with analysis of clinical and microbiological factors associated with patient outcomes","volume":"113","author":"Zhang Y","year":"2021","unstructured":"Zhang Y, Feng L, Wang X, et al.. Low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet compared with traditional dietary advice for diarrhea-predominant irritable bowel syndrome: a parallel-group, randomized controlled trial with analysis of clinical and microbiological factors associated with patient outcomes. Am J Clin Nutr. 2021, 113:1531-45. 10.1093\/ajcn\/nqab005","journal-title":"Am J Clin Nutr"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13286","article-title":"Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome","volume":"42","author":"Chumpitazi BP","year":"2015","unstructured":"Chumpitazi BP, Cope JL, Hollister EB, et al.. Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome. Aliment Pharmacol Ther. 2015, 42:418-27. 10.1111\/apt.13286","journal-title":"Aliment Pharmacol Ther"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.06.044","article-title":"A diet low in fermentable oligo-, di-, and monosaccharides and\u00a0polyols improves quality of life and reduces activity\u00a0impairment in patients with irritable bowel syndrome\u00a0and diarrhea","volume":"15","author":"Eswaran S","year":"2017","unstructured":"Eswaran S, Chey WD, Jackson K, Pillai S, Chey SW, Han-Markey T. A diet low in fermentable oligo-, di-, and monosaccharides and\u00a0polyols improves quality of life and reduces activity\u00a0impairment in patients with irritable bowel syndrome\u00a0and diarrhea. Clin Gastroenterol Hepatol. 2017, 15:1890-1899.e3. 10.1016\/j.cgh.2017.06.044","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-09055-6","article-title":"Effects of a gluten challenge in patients with irritable bowel syndrome: a randomized single-blind controlled clinical trial","volume":"12","author":"Saadati S","year":"2022","unstructured":"Saadati S, Sadeghi A, Mohaghegh-Shalmani H, et al.. Effects of a gluten challenge in patients with irritable bowel syndrome: a randomized single-blind controlled clinical trial. Sci Rep. 2022, 12:4960. 10.1038\/s41598-022-09055-6","journal-title":"Sci Rep"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-021-01868-5","article-title":"Influence of low FODMAP-gluten free diet on gut microbiota alterations and symptom severity in Iranian patients with irritable bowel syndrome","volume":"21","author":"Naseri K","year":"2021","unstructured":"Naseri K, Dabiri H, Rostami-Nejad M, et al.. Influence of low FODMAP-gluten free diet on gut microbiota alterations and symptom severity in Iranian patients with irritable bowel syndrome. BMC Gastroenterol. 2021, 21:292. 10.1186\/s12876-021-01868-5","journal-title":"BMC Gastroenterol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s00394-019-02060-y","article-title":"Is Bacillus coagulans supplementation plus low FODMAP diet superior to low FODMAP diet in irritable bowel syndrome management?","volume":"59","author":"Abhari K","year":"2020","unstructured":"Abhari K, Saadati S, Hosseini-Oskouiee F, et al.. Is Bacillus coagulans supplementation plus low FODMAP diet superior to low FODMAP diet in irritable bowel syndrome management?. Eur J Nutr. 2020, 59:2111-7. 10.1007\/s00394-019-02060-y","journal-title":"Eur J Nutr"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.02.045","article-title":"Efficacy and acceptability of dietary therapies in non-constipated irritable bowel syndrome: a randomized trial of traditional dietary advice, the Low FODMAP diet, and the gluten-free diet","volume":"20","author":"Rej A","year":"2022","unstructured":"Rej A, Sanders DS, Shaw CC, Buckle R, Trott N, Agrawal A, Aziz I. Efficacy and acceptability of dietary therapies in non-constipated irritable bowel syndrome: a randomized trial of traditional dietary advice, the Low FODMAP diet, and the gluten-free diet. Clin Gastroenterol Hepatol. 2022, 20:2876-2887.e15. 10.1016\/j.cgh.2022.02.045","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3390\/nu14081544","article-title":"A comparison of the low-FODMAPs diet and a tritordeum-based diet on the gastrointestinal symptom profile of patients suffering from irritable bowel syndrome-diarrhea variant (IBS-D): a randomized controlled trial","volume":"14","author":"Russo F","year":"2022","unstructured":"Russo F, Riezzo G, Orlando A, et al.. A comparison of the low-FODMAPs diet and a tritordeum-based diet on the gastrointestinal symptom profile of patients suffering from irritable bowel syndrome-diarrhea variant (IBS-D): a randomized controlled trial. Nutrients. 2022, 14:1544. 10.3390\/nu14081544","journal-title":"Nutrients"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.5409\/wjcp.v11.i4.330","article-title":"Effects of adherence to the Mediterranean diet in children and adolescents with irritable bowel syndrome","volume":"11","author":"Al-Biltagi M","year":"2022","unstructured":"Al-Biltagi M, El Amrousy D, El Ashry H, Maher S, Mohammed MA, Hasan S. Effects of adherence to the Mediterranean diet in children and adolescents with irritable bowel syndrome. World J Clin Pediatr. 2022, 11:330-40. 10.5409\/wjcp.v11.i4.330","journal-title":"World J Clin Pediatr"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0673-5","article-title":"A review of microbiota and irritable bowel syndrome: future in therapies","volume":"35","author":"Rodi\u00f1o-Janeiro BK","year":"2018","unstructured":"Rodi\u00f1o-Janeiro BK, Vicario M, Alonso-Cotoner C, Pascua-Garc\u00eda R, Santos J. A review of microbiota and irritable bowel syndrome: future in therapies. Adv Ther. 2018, 35:289-310. 10.1007\/s12325-018-0673-5","journal-title":"Adv Ther"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3390\/nu13062112","article-title":"Probiotics, prebiotics, and synbiotics: implications and beneficial effects against irritable bowel syndrome","volume":"13","author":"Simon E","year":"2021","unstructured":"Simon E, C\u0103linoiu LF, Mitrea L, Vodnar DC. Probiotics, prebiotics, and synbiotics: implications and beneficial effects against irritable bowel syndrome. Nutrients. 2021, 13:2112. 10.3390\/nu13062112","journal-title":"Nutrients"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1177\/15598276211012968","article-title":"Dietary modification for the restoration of gut microbiome and management of symptoms in irritable bowel syndrome","volume":"16","author":"Thomas A","year":"2022","unstructured":"Thomas A, Thomas A, Butler-Sanchez M. Dietary modification for the restoration of gut microbiome and management of symptoms in irritable bowel syndrome. Am J Lifestyle Med. 2022, 16:608-21. 10.1177\/15598276211012968","journal-title":"Am J Lifestyle Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3390\/toxins14090596","article-title":"Gut non-bacterial microbiota: emerging link to irritable bowel syndrome","volume":"14","author":"Liu A","year":"2022","unstructured":"Liu A, Gao W, Zhu Y, Hou X, Chu H. Gut non-bacterial microbiota: emerging link to irritable bowel syndrome. Toxins (Basel). 2022, 14:596. 10.3390\/toxins14090596","journal-title":"Toxins (Basel)"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03911.x","article-title":"Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome","volume":"29","author":"Silk DB","year":"2009","unstructured":"Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther. 2009, 29:508-18. 10.1111\/j.1365-2036.2008.03911.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1017\/S0007114510003363","article-title":"Prebiotic effects: metabolic and health benefits","volume":"104","author":"Roberfroid M","year":"2010","unstructured":"Roberfroid M, Gibson GR, Hoyles L, et al.. Prebiotic effects: metabolic and health benefits. Br J Nutr. 2010, 104:S1-63. 10.1017\/S0007114510003363","journal-title":"Br J Nutr"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/nqy376","article-title":"Prebiotics in irritable bowel syndrome and other functional bowel disorders in adults: a systematic review and meta-analysis of randomized controlled trials","volume":"109","author":"Wilson B","year":"2019","unstructured":"Wilson B, Rossi M, Dimidi E, Whelan K. Prebiotics in irritable bowel syndrome and other functional bowel disorders in adults: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. 2019, 109:1098-111. 10.1093\/ajcn\/nqy376","journal-title":"Am J Clin Nutr"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1111\/apa.16107","article-title":"How to manage irritable bowel syndrome in children","volume":"111","author":"Levy EI","year":"2022","unstructured":"Levy EI, De Geyter C, Ouald Chaib A, Aman BA, Hegar B, Vandenplas Y. How to manage irritable bowel syndrome in children. Acta Paediatr. 2022, 111:24-34. 10.1111\/apa.16107","journal-title":"Acta Paediatr"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1097\/MCO.0b013e32834b8082","article-title":"Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews","volume":"14","author":"Whelan K","year":"2011","unstructured":"Whelan K. Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews. Curr Opin Clin Nutr Metab Care. 2011, 14:581-7. 10.1097\/MCO.0b013e32834b8082","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"ref45","article-title":"Probiotics: some evidence of their effectiveness","volume":"51","author":"Reid G","year":"2005","unstructured":"Reid G, Hammond JA. Probiotics: some evidence of their effectiveness. Can Fam Physician. 2005, 51:1487-93.","journal-title":"Can Fam Physician"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.3390\/nu11092048","article-title":"Probiotics in irritable bowel syndrome: an up-to-date systematic review","volume":"11","author":"Dale HF","year":"2019","unstructured":"Dale HF, Rasmussen SH, Asiller \u00d6\u00d6, Lied GA. Probiotics in irritable bowel syndrome: an up-to-date systematic review. Nutrients. 2019, 11:2048. 10.3390\/nu11092048","journal-title":"Nutrients"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15001","article-title":"Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome","volume":"48","author":"Ford AC","year":"2018","unstructured":"Ford AC, Harris LA, Lacy BE, Quigley EM, Moayyedi P. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2018, 48:1044-60. 10.1111\/apt.15001","journal-title":"Aliment Pharmacol Ther"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3390\/biom11081154","article-title":"Probiotics, prebiotics, and synbiotics in the irritable bowel syndrome treatment: a review","volume":"11","author":"Chlebicz-W\u00f3jcik A","year":"2021","unstructured":"Chlebicz-W\u00f3jcik A, \u015ali\u017cewska K. Probiotics, prebiotics, and synbiotics in the irritable bowel syndrome treatment: a review. Biomolecules. 2021, 11:1154. 10.3390\/biom11081154","journal-title":"Biomolecules"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.18295\/squmj.2020.20.01.003","article-title":"Efficacy and safety of probiotics, prebiotics and synbiotics in the treatment of irritable bowel syndrome: a systematic review and meta-analysis","volume":"20","author":"Asha MZ","year":"2020","unstructured":"Asha MZ, Khalil SF. Efficacy and safety of probiotics, prebiotics and synbiotics in the treatment of irritable bowel syndrome: a systematic review and meta-analysis. Sultan Qaboos Univ Med J. 2020, 20:e13-24. 10.18295\/squmj.2020.20.01.003","journal-title":"Sultan Qaboos Univ Med J"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.36565","article-title":"Probiotics in irritable bowel syndrome: a review article","volume":"15","author":"Sharma S","year":"2023","unstructured":"Sharma S, Kumar S, Sajjad S, Sharma S. Probiotics in irritable bowel syndrome: a review article. Cureus. 2023, 15:e36565. 10.7759\/cureus.36565","journal-title":"Cureus"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.5009\/gnl210478","article-title":"Efficacy of a synbiotic containing Lactobacillus paracasei DKGF1 and Opuntia humifusa in elderly patients with irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial","volume":"17","author":"Oh JH","year":"2023","unstructured":"Oh JH, Jang YS, Kang D, et al.. Efficacy of a synbiotic containing Lactobacillus paracasei DKGF1 and Opuntia humifusa in elderly patients with irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. Gut Liver. 2023, 17:100-7. 10.5009\/gnl210478","journal-title":"Gut Liver"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.4082\/kjfm.17.0064","article-title":"A randomized clinical trial of synbiotics in irritable bowel syndrome: dose-dependent effects on gastrointestinal symptoms and fatigue","volume":"40","author":"Lee SH","year":"2019","unstructured":"Lee SH, Cho DY, Lee SH, et al.. A randomized clinical trial of synbiotics in irritable bowel syndrome: dose-dependent effects on gastrointestinal symptoms and fatigue. Korean J Fam Med. 2019, 40:2-8. 10.4082\/kjfm.17.0064","journal-title":"Korean J Fam Med"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-111717-122956","article-title":"Clinical application and potential of fecal microbiota transplantation","volume":"70","author":"Ooijevaar RE","year":"2019","unstructured":"Ooijevaar RE, Terveer EM, Verspaget HW, Kuijper EJ, Keller JJ. Clinical application and potential of fecal microbiota transplantation. Annu Rev Med. 2019, 70:335-51. 10.1146\/annurev-med-111717-122956","journal-title":"Annu Rev Med"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/9759138","article-title":"Research progress in fecal microbiota transplantation as treatment for irritable bowel syndrome","volume":"2019","author":"Wang Y","year":"2019","unstructured":"Wang Y, Zheng F, Liu S, Luo H. Research progress in fecal microbiota transplantation as treatment for irritable bowel syndrome. Gastroenterol Res Pract. 2019, 2019:9759138. 10.1155\/2019\/9759138","journal-title":"Gastroenterol Res Pract"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i1.5","article-title":"Relationship between intestinal microbiota and ulcerative colitis: Mechanisms and clinical application of probiotics and fecal microbiota transplantation","volume":"24","author":"Shen ZH","year":"2018","unstructured":"Shen ZH, Zhu CX, Quan YS, et al.. Relationship between intestinal microbiota and ulcerative colitis: Mechanisms and clinical application of probiotics and fecal microbiota transplantation. World J Gastroenterol. 2018, 24:5-14. 10.3748\/wjg.v24.i1.5","journal-title":"World J Gastroenterol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.07.013","article-title":"Fecal microbiota transplantation reduces symptoms in some patients with irritable bowel syndrome with predominant abdominal bloating: short- and long-term results from a placebo-controlled randomized trial","volume":"160","author":"Holvoet T","year":"2021","unstructured":"Holvoet T, Joossens M, V\u00e1zquez-Castellanos JF, et al.. Fecal microbiota transplantation reduces symptoms in some patients with irritable bowel syndrome with predominant abdominal bloating: short- and long-term results from a placebo-controlled randomized trial. Gastroenterology. 2021, 160:145-157.e8. 10.1053\/j.gastro.2020.07.013","journal-title":"Gastroenterology"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/6981721","article-title":"Fecal microbiota transplantation research over the past decade: current status and trends","volume":"2023","author":"Hao S","year":"2023","unstructured":"Hao S, Yang S, Zhang N, Cheng H. Fecal microbiota transplantation research over the past decade: current status and trends. Can J Infect Dis Med Microbiol. 2023, 2023:6981721. 10.1155\/2023\/6981721","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1039284","article-title":"Fecal microbiota transplantation in irritable bowel syndrome: a meta-analysis of randomized controlled trials","volume":"9","author":"Samuthpongtorn C","year":"2022","unstructured":"Samuthpongtorn C, Kantagowit P, Pittayanon R, Patcharatrakul T, Gonlachanvit S. Fecal microbiota transplantation in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Front Med (Lausanne). 2022, 9:1039284. 10.3389\/fmed.2022.1039284","journal-title":"Front Med (Lausanne)"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2020.1794263","article-title":"Effects of fecal microbiota transplantation in subjects with irritable bowel syndrome are mirrored by changes in gut microbiome","volume":"12","author":"Goll R","year":"2020","unstructured":"Goll R, Johnsen PH, Hjerde E, Diab J, Valle PC, Hilpusch F, Cavanagh JP. Effects of fecal microbiota transplantation in subjects with irritable bowel syndrome are mirrored by changes in gut microbiome. Gut Microbes. 2020, 12:1794263. 10.1080\/19490976.2020.1794263","journal-title":"Gut Microbes"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.827395","article-title":"Efficacy of fecal microbiota transplantation in irritable bowel syndrome: a meta-analysis of randomized controlled trials","volume":"12","author":"Wu J","year":"2022","unstructured":"Wu J, Lv L, Wang C. Efficacy of fecal microbiota transplantation in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Front Cell Infect Microbiol. 2022, 12:827395. 10.3389\/fcimb.2022.827395","journal-title":"Front Cell Infect Microbiol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms10071332","article-title":"Gut microbiota manipulation in irritable bowel syndrome","volume":"10","author":"Mazzawi T","year":"2022","unstructured":"Mazzawi T. Gut microbiota manipulation in irritable bowel syndrome. Microorganisms. 2022, 10:1332. 10.3390\/microorganisms10071332","journal-title":"Microorganisms"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw224","article-title":"Bacteriophages targeting adherent invasive Escherichia coli strains as a promising new treatment for Crohn's disease","volume":"11","author":"Galtier M","year":"2017","unstructured":"Galtier M, De Sordi L, Sivignon A, et al.. Bacteriophages targeting adherent invasive Escherichia coli strains as a promising new treatment for Crohn's disease. J Crohns Colitis. 2017, 11:840-7. 10.1093\/ecco-jcc\/jjw224","journal-title":"J Crohns Colitis"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1206-1508","article-title":"Reinventing phage therapy: are the parts greater than the sum?","volume":"24","author":"Fischetti VA","year":"2006","unstructured":"Fischetti VA, Nelson D, Schuch R. Reinventing phage therapy: are the parts greater than the sum?. Nat Biotechnol. 2006, 24:1508-11. 10.1038\/nbt1206-1508","journal-title":"Nat Biotechnol"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1038\/nature05762","article-title":"Herpesvirus latency confers symbiotic protection from bacterial infection","volume":"447","author":"Barton ES","year":"2007","unstructured":"Barton ES, White DW, Cathelyn JS, et al.. Herpesvirus latency confers symbiotic protection from bacterial infection. Nature. 2007, 447:326-9. 10.1038\/nature05762","journal-title":"Nature"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2018.2","article-title":"Gut microbiota-based therapies for irritable bowel syndrome","volume":"9","author":"Stern EK","year":"2018","unstructured":"Stern EK, Brenner DM. Gut microbiota-based therapies for irritable bowel syndrome. Clin Transl Gastroenterol. 2018, 9:e134. 10.1038\/ctg.2018.2","journal-title":"Clin Transl Gastroenterol"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i11.3361","article-title":"New therapeutic option for irritable bowel syndrome: serum-derived bovine immunoglobulin","volume":"21","author":"Good L","year":"2015","unstructured":"Good L, Rosario R, Panas R. New therapeutic option for irritable bowel syndrome: serum-derived bovine immunoglobulin. World J Gastroenterol. 2015, 21:3361-6. 10.3748\/wjg.v21.i11.3361","journal-title":"World J Gastroenterol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S62823","article-title":"Serum-derived bovine immunoglobulin\/protein isolate: postulated mechanism of action for management of enteropathy","volume":"7","author":"Petschow BW","year":"2014","unstructured":"Petschow BW, Burnett B, Shaw AL, Weaver EM, Klein GL. Serum-derived bovine immunoglobulin\/protein isolate: postulated mechanism of action for management of enteropathy. Clin Exp Gastroenterol. 2014, 7:181-90. 10.2147\/CEG.S62823","journal-title":"Clin Exp Gastroenterol"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.13170","article-title":"Potential mechanisms of effects of serum-derived bovine immunoglobulin\/protein isolate therapy in patients with diarrhea-predominant irritable bowel syndrome","volume":"5","author":"Valentin N","year":"2017","unstructured":"Valentin N, Camilleri M, Carlson P, et al.. Potential mechanisms of effects of serum-derived bovine immunoglobulin\/protein isolate therapy in patients with diarrhea-predominant irritable bowel syndrome. Physiol Rep. 2017, 5:e13170. 10.14814\/phy2.13170","journal-title":"Physiol Rep"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/4579850","article-title":"A network pharmacology-based study on irritable bowel syndrome prevention and treatment Utilizing Shenling Baizhu powder","volume":"2021","author":"Meng M","year":"2021","unstructured":"Meng M, Bai C, Wan B, Zhao L, Li Z, Li D, Zhang S. A network pharmacology-based study on irritable bowel syndrome prevention and treatment Utilizing Shenling Baizhu powder. Biomed Res Int. 2021, 2021:4579850. 10.1155\/2021\/4579850","journal-title":"Biomed Res Int"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctim.2022.102839","article-title":"Assessing the post-treatment therapeutic effect of tongxie in irritable bowel syndrome: A randomized controlled trial","volume":"68","author":"Lai Y","year":"2022","unstructured":"Lai Y, Liang X, Fan H, et al.. Assessing the post-treatment therapeutic effect of tongxie in irritable bowel syndrome: A randomized controlled trial. Complement Ther Med. 2022, 68:102839. 10.1016\/j.ctim.2022.102839","journal-title":"Complement Ther Med"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025604","article-title":"Comparison of acupuncture and pinaverium bromide in the treatment of irritable bowel syndrome: a protocol for systematic review and meta-analysis","volume":"100","author":"Li H","year":"2021","unstructured":"Li H, Chen Y, Hu Z, et al.. Comparison of acupuncture and pinaverium bromide in the treatment of irritable bowel syndrome: a protocol for systematic review and meta-analysis. Medicine (Baltimore). 2021, 100:e25604. 10.1097\/MD.0000000000025604","journal-title":"Medicine (Baltimore)"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.3390\/nu10111715","article-title":"Herbs and spices in the treatment of functional gastrointestinal disorders: a review of clinical trials","volume":"10","author":"Fifi AC","year":"2018","unstructured":"Fifi AC, Axelrod CH, Chakraborty P, Saps M. Herbs and spices in the treatment of functional gastrointestinal disorders: a review of clinical trials. Nutrients. 2018, 10:1715. 10.3390\/nu10111715","journal-title":"Nutrients"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.694741","article-title":"Chinese herbal medicine for irritable bowel syndrome: a meta-analysis and trial sequential analysis of randomized controlled trials","volume":"12","author":"Zheng H","year":"2021","unstructured":"Zheng H, Jin S, Shen YL, et al.. Chinese herbal medicine for irritable bowel syndrome: a meta-analysis and trial sequential analysis of randomized controlled trials. Front Pharmacol. 2021, 12:694741. 10.3389\/fphar.2021.694741","journal-title":"Front Pharmacol"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8213082","article-title":"Efficacy and safety of a novel herbal medicine in the treatment of irritable bowel syndrome: a randomized double-blinded clinical trial","volume":"2020","author":"Bordbar G","year":"2020","unstructured":"Bordbar G, Miri MB, Omidi M, Shoja S, Akhavan M. Efficacy and safety of a novel herbal medicine in the treatment of irritable bowel syndrome: a randomized double-blinded clinical trial. Gastroenterol Res Pract. 2020, 2020:8213082. 10.1155\/2020\/8213082","journal-title":"Gastroenterol Res Pract"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1186\/s12906-018-2409-0","article-title":"The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data","volume":"19","author":"Alammar N","year":"2019","unstructured":"Alammar N, Wang L, Saberi B, Nanavati J, Holtmann G, Shinohara RT, Mullin GE. The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data. BMC Complement Altern Med. 2019, 19:21. 10.1186\/s12906-018-2409-0","journal-title":"BMC Complement Altern Med"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.3390\/nu14194208","article-title":"Geraniol treatment for irritable bowel syndrome: a double-blind randomized clinical trial","volume":"14","author":"Ricci C","year":"2022","unstructured":"Ricci C, Rizzello F, Valerii MC, et al.. Geraniol treatment for irritable bowel syndrome: a double-blind randomized clinical trial. Nutrients. 2022, 14:4208. 10.3390\/nu14194208","journal-title":"Nutrients"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.48817","article-title":"Acupuncture for the treatment of diarrhea-predominant irritable bowel syndrome: a pilot randomized clinical trial","volume":"5","author":"Qi LY","year":"2022","unstructured":"Qi LY, Yang JW, Yan SY, et al.. Acupuncture for the treatment of diarrhea-predominant irritable bowel syndrome: a pilot randomized clinical trial. JAMA Netw Open. 2022, 5:e2248817. 10.1001\/jamanetworkopen.2022.48817","journal-title":"JAMA Netw Open"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1067329","article-title":"Acupuncture and related therapies for the anxiety and depression in irritable bowel syndrome with diarrhea (IBS-D): A network meta-analysis of randomized controlled trials","volume":"13","author":"Wang X","year":"2022","unstructured":"Wang X, Shi X, Lv J, et al.. Acupuncture and related therapies for the anxiety and depression in irritable bowel syndrome with diarrhea (IBS-D): A network meta-analysis of randomized controlled trials. Front Psychiatry. 2022, 13:1067329. 10.3389\/fpsyt.2022.1067329","journal-title":"Front Psychiatry"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-045655","article-title":"Efficacy of acupuncture in refractory irritable bowel syndrome: study protocol for a randomised controlled trial","volume":"11","author":"Zhao J","year":"2021","unstructured":"Zhao J, Chen M, Wang X, et al.. Efficacy of acupuncture in refractory irritable bowel syndrome: study protocol for a randomised controlled trial. BMJ Open. 2021, 11:e045655. 10.1136\/bmjopen-2020-045655","journal-title":"BMJ Open"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011627","article-title":"Electroacupuncture for patients with irritable bowel syndrome: a systematic review and meta-analysis protocol","volume":"97","author":"Zhang Y","year":"2018","unstructured":"Zhang Y, Li Z, Han F. Electroacupuncture for patients with irritable bowel syndrome: a systematic review and meta-analysis protocol. Medicine (Baltimore). 2018, 97:e11627. 10.1097\/MD.0000000000011627","journal-title":"Medicine (Baltimore)"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.1022145","article-title":"Clinical evidence of acupuncture and moxibustion for irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Yang Y","year":"2022","unstructured":"Yang Y, Rao K, Zhan K, et al.. Clinical evidence of acupuncture and moxibustion for irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Front Public Health. 2022, 10:1022145. 10.3389\/fpubh.2022.1022145","journal-title":"Front Public Health"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9919839","article-title":"Acupuncture and moxibustion in the treatment of adult diarrhea irritable bowel syndrome: a network meta-analysis","volume":"2022","author":"Jiang X","year":"2022","unstructured":"Jiang X, Guo X, Zhou J, Ye S. Acupuncture and moxibustion in the treatment of adult diarrhea irritable bowel syndrome: a network meta-analysis. Comput Math Methods Med. 2022, 2022:9919839. 10.1155\/2022\/9919839","journal-title":"Comput Math Methods Med"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1080\/00207144.2019.1553766","article-title":"Skype hypnotherapy for irritable bowel syndrome: effectiveness and comparison with face-to-face treatment","volume":"67","author":"Hasan SS","year":"2019","unstructured":"Hasan SS, Pearson JS, Morris J, Whorwell PJ. Skype hypnotherapy for irritable bowel syndrome: effectiveness and comparison with face-to-face treatment. Int J Clin Exp Hypn. 2019, 67:69-80. 10.1080\/00207144.2019.1553766","journal-title":"Int J Clin Exp Hypn"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.03.063","article-title":"Improvement in gastrointestinal symptoms after cognitive behavior therapy for refractory irritable bowel syndrome","volume":"155","author":"Lackner JM","year":"2018","unstructured":"Lackner JM, Jaccard J, Keefer L, et al.. Improvement in gastrointestinal symptoms after cognitive behavior therapy for refractory irritable bowel syndrome. Gastroenterology. 2018, 155:47-57. 10.1053\/j.gastro.2018.03.063","journal-title":"Gastroenterology"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1093\/jcag\/gwac028","article-title":"Gastroenterologist and patient attitudes toward yoga as a therapy for irritable bowel syndrome: an application of the theory of planned behaviour","volume":"6","author":"D'Silva A","year":"2023","unstructured":"D'Silva A, Marshall DA, Vallance JK, Nasser Y, Taylor LM, Lazarescu A, Raman M. Gastroenterologist and patient attitudes toward yoga as a therapy for irritable bowel syndrome: an application of the theory of planned behaviour. J Can Assoc Gastroenterol. 2023, 6:17-25. 10.1093\/jcag\/gwac028","journal-title":"J Can Assoc Gastroenterol"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-321191","article-title":"Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis","volume":"69","author":"Black CJ","year":"2020","unstructured":"Black CJ, Thakur ER, Houghton LA, Quigley EM, Moayyedi P, Ford AC. Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. Gut. 2020, 69:1441-51. 10.1136\/gutjnl-2020-321191","journal-title":"Gut"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/174941-irritable-bowel-syndrome-treating-the-gut-and-brainmind-at-the-same-time","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:01:22Z","timestamp":1707508882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/174941-irritable-bowel-syndrome-treating-the-gut-and-brainmind-at-the-same-time"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,13]]},"references-count":86,"URL":"https:\/\/doi.org\/10.7759\/cureus.43404","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,13]]}}}